• Title/Summary/Keyword: Thyroid Uptake

Search Result 142, Processing Time 0.014 seconds

Investigations of the External Dose Rate (${\mu}Sv/h$), the Residual Activity (mCi) and the Excretion Rate (%) of Thyroid Cancer Patients Hospitalized for 3700 MBq (100 mCi) $^{131}I$ Radioiodine Treatment ($^{131}I$ 3700 MBq (100 mCi) Therapy 입원 환자의 선량률(${\mu}Sv/h$), 잔류량(mCi), 배설률(%) 측정)

  • Bae, Gi-Han;Kim, Hwa-Joong;Choi, Jae-Jin;Lee, Won-Guk
    • The Korean Journal of Nuclear Medicine Technology
    • /
    • v.13 no.3
    • /
    • pp.48-55
    • /
    • 2009
  • Purpose: As Korean nuclear law doesn't have any clear guideline about the dose and the external dose rate(uSv/h) requiring hospitalization in radioactive iodine treated patients, the patients are discharged when they meet the guideline of IAEA Basic Safety Standards(BSS). We measured external dose rate(${\mu}Sv/h$) of inpatient underwent 3700MBq (100 mCi) $^{131}I$ radioiodine treatment and considering external dose rate(${\mu}Sv/h$), residual activity(mCi) and excretion rate(%) we found the time for RA to be lowered from 3700MBq (100 mCi) to 1110 MBq (30 mCi) to give reference to set a guideline for discharge. Materials and Methods: Forty-two patients underwent thyroidectomy and scheduled for radioiodine treatment, who received 3700MBq (100 mCi) of $^{131}I$ orally and had no renal disease were examined. After 1, 2, 4, 8, and 20, 24, 40 hours iodine uptake and before/after the urination, the external dose rate(${\mu}Sv/h$) measured using FH40G-L(Thermo Fisher Scientific Inc., MA) at a distance and a height of 1 m for 20 sec on the average. Results and Conclusions: At 20 hours, the external dose rate was decreased to $49{\pm}13\;{\mu}Sv$/h, namely, 78% of administrated radioactivity was excreted and 814 MBq (30 mCi) was residual, and it met the accepted limit for discharge of (IAEA, BSS) under 1110 MBq (30 mCi) (1 m at 66 uSv/h).

  • PDF

Biodistribution of Iodine-131-Iodomisonidazole and Imaging of Tumor Hypoxia in Mice bearing CT-26 Adenocarcinoma (CT-26 선암을 접종한 마우스에서 Iodine-131-Iodomisonidazole의 생체분포 및 종양저산소증의 영상화)

  • Kim, Hye-Won;Kim, Chang-Guhn;Yoon, Kwon-Ha;Kim, Hyun-Jeong;Juhng Seon-Kwan;Roh, Byung-Suk;Yang, David J.;Kim, E.Edmund;Lee, Hyun-Chul
    • The Korean Journal of Nuclear Medicine
    • /
    • v.33 no.3
    • /
    • pp.289-297
    • /
    • 1999
  • Purpose: Misonidazole is a radiosensitizer that binds in hypoxic cells. The purpose of this study was to find out the feasibility of I-131-Iodomisonidazole (IMISO) for imaging of tumor hypoxia. Materials and Methods: Tosyl precursor was dissolved in acetonitrile and I-131-NaI was added to synthesize IMISO. Balb/c mice inoculated with CT-26 adenocarcinoma were injected with IMISO. Mice were sacrificed at 1, 2, 4, 24 hr and % of injected dose per gram of tissue (%ID/g) was determined. For scintigraphy and MRI, mouse bearing CT-26 adenocarcinoma was administered with IMISO and imaging was performed 4 hr after. Then, mouse body was fixed and microtomized slice was placed on radiographic film for autoradiography Results: %ID/g of tumor was 1.64 (1h), 0.98 (2h), 0.85 (4h) and 0.20 (24h), respectively. At 24h, %ID/g of tumor was higher than that of all other tissues except thyroid. Tumor to muscle ratio increased with time and tumor to blood ratio also increased with time and reached 1.53 at 24 hr. On autoradiogram, tumor was well visualized as an increased activity in central hypoxic area of the tumor which corresponds to the area of high signal intensity on T2-weighted MR image. On scintigraphy, tumor uptake was visualized. Conclusion: This results suggest that IMISO may have a potential for tumor hypoxia imaging in mouse model. However, further study is needed to improve it's localization in tumor tissue and to achieve acceptable images of tumor hypoxia.

  • PDF